Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent

Hypertension

Volumn 65, Issue 1, 2015, Pages 238-249

  Jackson, Edwin K ^a   Mi, Zaichuan ^a   Tofovic, Stevan P ^a   Gillespie, Delbert G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dipeptidyl Peptidase 4; Sitagliptin; Spontaneously Hypertensive Rat; Wistar Kyoto Rat; Y1 Receptor

Indexed keywords

ENALAPRIL; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; HYDRALAZINE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NORADRENALIN; PLERIXAFOR; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG POTENCY; ELEVATED BLOOD PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TELEMETRY; VASOCONSTRICTION; WISTAR KYOTO RAT; ZUCKER DIABETIC FATTY RAT; ANIMAL; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ANIMALS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HYPERTENSION; MALE; PYRAZINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84919443247     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04631     Document Type: Article

References (48)

1. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454-1470.
2. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep. 2009;11:150-155.
3. Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012;60:467-473.
4. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60:833-841.
5. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598.
6. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223:133-135.
7. Pacheco BP, Crajoinas RO, Couto GK, Davel AP, Lessa LM, Rossoni LV, Girardi AC. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011;29:520-528.
8. Jackson EK, Dubinion JH, Mi Z. Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. Clin Exp Pharmacol Physiol. 2008;35:29-34.
9. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728-733.
10. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause- Relle K, Raila J, Henze A, Klein T, Hocher B. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36:119-130.
11. Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, Kutil B, Kraft R, Klein T, Hocher B. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens. 2013;31:2290-2299.
12. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005;108:277-292.
13. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
14. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575.
15. Zhang K, Rao F, Miramontes-Gonzalez JP, et al. Neuropeptide Y (NPY): genetic variation in the human promoter alters glucocorticoid signaling, yielding increased NPY secretion and stress responses. J Am Coll Cardiol. 2012;60:1678-1689.
16. Bou SM, Isakova IA, Burow ME, Cao H, Bhatnagar D, Sarver JG, Shinde KV, Erhardt PW, Heiman ML. Glyceollins, soy isoflavone phytoalexins, improve oral glucose disposal by stimulating glucose uptake. J Agric Food Chem. 2012;60:6376-6382.
17. Davis JE, Cain J, Banz WJ, Peterson RG. Age-related changes in hepatic activity and expression of detoxification enzymes in male rats. BioMed Res Int. 2013;2013:10.
18. Gao L, Zhu C, Jackson EK. α2-Adrenoceptors potentiate angiotensin IIand vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2003;305:581-586.
19. Jackson EK, Gao L, Zhu C. Mechanism of the vascular angiotensin II/α2-adrenoceptor interaction. J Pharmacol Exp Ther. 2005;314:1109-1116.
20. Jackson EK, Gillespie DG, Zhu C, Ren J, Zacharia LC, Mi Z. α2-Adrenoceptors enhance angiotensin II-induced renal vasoconstriction: role for NADPH oxidase and RhoA. Hypertension. 2008;51:719-726.
21. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension. 2008;51:1637-1642.
22. Jackson EK, Zhang M, Liu W, Mi Z. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2007;323:431-437.
23. Giannocco G, Oliveira KC, Crajoinas RO, Venturini G, Salles TA, Fonseca-Alaniz MH, Maciel RM, Girardi AC. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur J Pharmacol. 2013;698:74-86.
24. Tough IR, Cox HM. Selective inhibition of neuropeptide Y Y1 receptors by BIBP3226 in rat and human epithelial preparations. Eur J Pharmacol. 1996;310:55-60.
25. Jackson DN, Milne KJ, Noble EG, Shoemaker JK. Gender-modulated endogenous baseline neuropeptide Y Y1-receptor activation in the hindlimb of Sprague-Dawley rats. J Physiol. 2005;562(pt 1):285-294.
26. Doods HN, Wienen W, Entzeroth M, Rudolf K, Eberlein W, Engel W, Wieland HA. Pharmacological characterization of the selective nonpeptide neuropeptide Y Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther. 1995;275:136-142.
27. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, Leurs R. Pharmacological modulation of chemokine receptor function. Br J Pharmacol. 2012;165:1617-1643.
28. Singh AK, Arya RK, Trivedi AK, Sanyal S, Baral R, Dormond O, Briscoe DM, Datta D. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12. Cytokine Growth Factor Rev. 2013;24:41-49.
29. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res. 2012;36:65-84.
30. Chu PY, Zatta A, Kiriazis H, Chin-Dusting J, Du XJ, Marshall T, Kaye DM. CXCR4 antagonism attenuates the cardiorenal consequences of mineralocorticoid excess. Circ Heart Fail. 2011;4:651-658.
31. Ruscher K, Kuric E, Liu Y, Walter HL, Issazadeh-Navikas S, Englund E, Wieloch T. Inhibition of CXCL12 signaling attenuates the postischemic immune response and improves functional recovery after stroke. J Cereb Blood Flow Metab. 2013;33:1225-1234.
32. Dubinion JH, Mi Z, Jackson EK. Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2006;317:1330-1336.
33. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK. Pancreatic polypeptidefold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension. 2006;47:545-551.
34. Gao L, Zhu C, Jackson EK. α2-Adrenoceptors potentiate angiotensin IIand vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2003;305:581-586.
35. Chatziantoniou C, Ruan X, Arendshorst WJ. Defective G protein activation of the cAMP pathway in rat kidney during genetic hypertension. Proc Natl Acad Sci U S A. 1995;92:2924-2928.
36. Ruan X, Chatziantoniou C, Arendshorst WJ. Impaired prostaglandin E2/prostaglandin I2 receptor-Gs protein interactions in isolated renal resistance arterioles of spontaneously hypertensive rats. Hypertension. 1999;34:1134-1140.
37. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431-439.
38. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760.
39. Aroor AR, Sowers JR, Bender SB, Nistala R, Garro M, Mugerfeld I, Hayden MR, Johnson MS, Salam M, Whaley-Connell A, Demarco VG. Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology. 2013;154:2501-2513.
40. Gradin KA, Li JY, Andersson O, Simonsen U. Enhanced neuropeptide Y immunoreactivity and vasoconstriction in mesenteric small arteries from spontaneously hypertensive rats. J Vasc Res. 2003;40:252-265.
41. Byku M, Macarthur H, Westfall TC. Nerve stimulation induced overflow of neuropeptide Y and modulation by angiotensin II in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2008;295:H2188-H2197.
42. Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ, Herring N. Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2013;305:H980-H986.
43. Odar-Cederlöf I, Ericsson F, Theodorsson E, Kjellstrand CM. Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis. 1998;31:803-808.
44. Wocial B, Ignatowska-Switalska H, Pruszczyk P, Jedrusik P, Januszewicz A, Lapinski M, Januszewicz W, Zukowska-Grojec Z. Plasma neuropeptide Y and catecholamines in women and men with essential hypertension. Blood Press. 1995;4:143-147.
45. Zhang X, Qi Q, Liang J, Hu FB, Sacks FM, Qi L. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial. Hypertension. 2012;60:1169-1175.
46. Scirica BM, Bhatt DL, Braunwald E; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
47. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A, Lundberg JM. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res. 1990;24:102-108.
48. Maisel AS, Scott NA, Motulsky HJ, Michel MC, Boublik JH, Rivier JE, Ziegler M, Allen RS, Brown MR. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med. 1989;86:43-48.